LOS ANGELES, CA, USA I September 15, 2021 I T-Cure Bioscience, Inc., a privately held company focused on developing autologous T cell receptor therapy (TCR-T) products for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate a Phase I clinical study evaluating a TCR-based product candidate for the treatment of tumors expressing Kita-Kyushu lung cancer antigen 1 (KK-LC-1), such as gastric, cervical, lung, breast cancers and other KK-LC-1 positive epithelial cancers (NCT05035407). T-Cure acquired the KK-LC-1 TCR therapy under an exclusive, worldwide license with the National Cancer Institute (NCI) in 2020. This Phase I Clinical Study will be conducted and sponsored by the NCI, part of the National Institutes of Health, where Dr. Scott Norberg and Dr. James Gulley will be the main PIs for this investigator-initiated trial. The trial will be done under a Cooperative Research and Development Agreement (CRADA) that T-Cure has in place with the NCI.

Last year, T-Cure entered into an exclusive, worldwide license with the NCI for intellectual property related to autologous TCR-T treatment of tumors expressing KK-LC-1, such as gastric, lung, triple negative breast and cervical cancers.

KK-LC-1 is a cancer germline (CG) antigen that has restricted expression in healthy tissues and frequent expression in epithelial cancers including lung cancer, gastric cancer, triple negative breast cancer, cervical cancer and others. Adoptive T-cell therapy is one potentially powerful treatment for cancer that genetically modifies natural T cells to make them tumor-specific and to improve their ability to destroy tumor cells. TCR-T cell therapy targeting CG antigens has been shown to induce objective responses without autoimmunity or off-target toxicity in patients with melanoma, synovial sarcoma and cervical carcinoma.

“TCR-T cell therapy is a promising new treatment modality that has demonstrated clinical activity in a subset of solid tumors.” stated Scott Norberg, D.O., Assistant Research Physician, Genitourinary Malignancies Branch, of CCR NCI and Principal Investigator of the study. “Our hope is that KK-LC-1 TCR-T cell therapy can be effective against common epithelial cancers, which account for 80-90% of all human malignancies.”

“We are excited that NCI has obtained the regulatory approval from FDA to initiate a first-in-human trial against a very important target in multiple solid tumors.” stated Gang Zeng, Ph.D., Chief Executive Officer of T-Cure Bioscience. “Dr. Norberg and Dr. Gulley have extensive experiences in developing novel adoptive T-cell therapies for cancer and they will be invaluable as we advance this program.”

Of note, the TCR was isolated from the tumor-infiltrating lymphocytes of a patient who had a complete response to an immunotherapy without any toxicities. As a result, it may hold great promise for engineering patients’ immune cells to effectively target and destroy cancer cells without harming healthy tissue.

About T-Cure Bioscience, Inc.

T-Cure Bioscience, Inc. is an innovative immuno-oncology company committed to delivering effective and durable cell therapies for the treatment of cancer. The Company focuses on developing high avidity TCR that can be used to engineer a patient’s T cells to effectively target and destroy solid tumors. The Company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1 novel antigens associated with solid tumors with significant unmet medical needs, including kidney cancer, triple negative breast cancer, lung cancer, gastric cancer and others.

SOURCE: T-Cure Bioscience